ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

In the Cancer Centers: Margaret Kripke of M.D. Anderson to Retire in 2007.

June 16, 2006

Varmus: Plan Would Give Trials A Strong Scientific Base

December 17, 2010

Concepts Approved for Primary Care, Worker Health, Black Interventions

May 17, 1985

Raising NIH Appropriations Is High Priority, House Subcommittee Chairman Says

March 7, 1997

Zerhouni Announces Changes To NIH Peer Review.

June 6, 2008

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013